S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Demand for grocery delivery cools as food costs rise
Musk says Twitter deal could move ahead with 'bot' info
Shift in war's front seen as ships cleared to leave Ukraine
Dems' climate, energy, tax bill clears initial Senate hurdle
Dems push Biden climate, health priorities toward Senate OK
Transit woes mount for Boston's beleaguered subway riders
pixel
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Demand for grocery delivery cools as food costs rise
Musk says Twitter deal could move ahead with 'bot' info
Shift in war's front seen as ships cleared to leave Ukraine
Dems' climate, energy, tax bill clears initial Senate hurdle
Dems push Biden climate, health priorities toward Senate OK
Transit woes mount for Boston's beleaguered subway riders
pixel
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Demand for grocery delivery cools as food costs rise
Musk says Twitter deal could move ahead with 'bot' info
Shift in war's front seen as ships cleared to leave Ukraine
Dems' climate, energy, tax bill clears initial Senate hurdle
Dems push Biden climate, health priorities toward Senate OK
Transit woes mount for Boston's beleaguered subway riders
pixel
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Demand for grocery delivery cools as food costs rise
Musk says Twitter deal could move ahead with 'bot' info
Shift in war's front seen as ships cleared to leave Ukraine
Dems' climate, energy, tax bill clears initial Senate hurdle
Dems push Biden climate, health priorities toward Senate OK
Transit woes mount for Boston's beleaguered subway riders
pixel
OTCMKTS:ALPMY

Astellas Pharma (ALPMY) Stock Forecast, Price & News

$14.96
+0.01 (+0.07%)
(As of 08/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$14.87
$14.96
50-Day Range
$14.61
$16.21
52-Week Range
$14.21
$18.18
Volume
67,658 shs
Average Volume
98,765 shs
Market Capitalization
$27.46 billion
P/E Ratio
27.20
Dividend Yield
1.83%
Price Target
N/A

Astellas Pharma MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.00% of Shares Sold Short
Dividend Strength
Moderate
Based on Four Factors
Sustainability
N/A
News Sentiment
0.34mentions of Astellas Pharma in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
8.99%
From $0.89 to $0.97 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.90 out of 5 stars

Astellas Pharma logo

About Astellas Pharma (OTCMKTS:ALPMY) Stock

Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant. The company also offers mirabegron for the treatment of neurogenic detrusor overactivity in pediatric patients; Vesicare for OAB treatment; Eligard to treat prostate cancer; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent. The company has a clinical trial collaboration with Merck & Co., Inc.; CytomX Therapeutics, Inc.; and an agreement with BANDAI NAMCO Entertainment Inc. for the development of smartphone exercise support application. It also has strategic research alliance with Harvard University for the research and development of therapeutics and technologies of mutual interest; research collaboration with Actinium Pharmaceuticals, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platform, as well as agreement with Zenith Epigenetics Ltd. to evaluate ZEN-3694; and collaboration agreement with Cytokinetics, Incorporated. The company has a strategic collaboration and license agreement with Minovia Therapeutics Ltd. for the research, development, and commercialization of cell therapy programs for diseases caused by mitochondrial dysfunction. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.

Receive ALPMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Astellas Pharma and its competitors with MarketBeat's FREE daily newsletter.

ALPMY Stock News Headlines

Astellas Announces Management Structure
Astellas Pharma Inc ADR Stock Quote ALPMY
Astellas Pharma Inc. (4503)
See More Headlines

Receive ALPMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Astellas Pharma and its competitors with MarketBeat's FREE daily newsletter.

ALPMY Company Calendar

Last Earnings
4/27/2021
Today
8/07/2022
Fiscal Year End
3/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:ALPMY
Fax
N/A
Employees
15,455
Year Founded
1923

Profitability

Net Income
$1.10 billion
Pretax Margin
12.10%

Debt

Sales & Book Value

Annual Sales
$11.55 billion
Cash Flow
$0.99 per share
Book Value
$7.08 per share

Miscellaneous

Outstanding Shares
1,835,850,000
Free Float
N/A
Market Cap
$27.46 billion
Optionable
Not Optionable
Beta
0.52

Social Links


Key Executives

  • Mr. Kenji Yasukawa Ph.D. (Age 62)
    Pres, CEO & Chairman
    Comp: $2.17M
  • Mr. Naoki Okamura BSc
    Exec. VP, Chief Strategy Officer & Representative Director
  • Minoru Kikuoka
    CFO & Sr. Managing Exec. Officer
  • Nobue Yasuda
    Gen. Mang. of Fin. & Accounting Department
  • Mr. Yoshitsugu Shitaka Ph.D.
    Chief Scientific Officer & Sr. Managing Exec. Officer
  • Mr. Fumiaki Sakurai
    Chief Admin. Officer, Chief Ethics & Compliance Officer and Sr. Corp. Exec.
  • Ms. Catherine B. Levitt
    Gen. Counsel
  • Mr. Stig Ogata
    VP of Corp. Communications
  • Ms. Collette Taylor (Age 59)
    Sr. VP of HR
  • Chihiro Yokota
    Sr. Corp. Exec. and Head of Japan/Asia Devel., Devel.













ALPMY Stock - Frequently Asked Questions

Should I buy or sell Astellas Pharma stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Astellas Pharma in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Astellas Pharma stock.
View analyst ratings for Astellas Pharma
or view top-rated stocks.

How has Astellas Pharma's stock performed in 2022?

Astellas Pharma's stock was trading at $16.27 at the start of the year. Since then, ALPMY shares have decreased by 8.1% and is now trading at $14.96.
View the best growth stocks for 2022 here
.

Are investors shorting Astellas Pharma?

Astellas Pharma saw a decrease in short interest in July. As of July 15th, there was short interest totaling 66,800 shares, a decrease of 63.5% from the June 30th total of 183,100 shares. Based on an average trading volume of 144,000 shares, the days-to-cover ratio is presently 0.5 days.
View Astellas Pharma's Short Interest
.

How were Astellas Pharma's earnings last quarter?

Astellas Pharma Inc. (OTCMKTS:ALPMY) posted its quarterly earnings data on Tuesday, April, 27th. The company reported ($0.06) EPS for the quarter, missing the consensus estimate of $0.22 by $0.28. The firm had revenue of $2.91 billion for the quarter. Astellas Pharma had a net margin of 8.91% and a trailing twelve-month return on equity of 8.62%.

Is Astellas Pharma a good dividend stock?

Astellas Pharma(OTCMKTS:ALPMY) pays an annual dividend of $0.27 per share and currently has a dividend yield of 1.83%. The dividend payout ratio of Astellas Pharma is 49.09%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Astellas Pharma will have a dividend payout ratio of 27.84% next year. This indicates that Astellas Pharma will be able to sustain or increase its dividend.

When did Astellas Pharma's stock split? How did Astellas Pharma's stock split work?

Astellas Pharma's stock split on the morning of Wednesday, April 2nd 2014. The 5-4 split was announced on Friday, March 14th 2014. The newly minted shares were payable to shareholders after the market closes on Tuesday, April 1st 2014. An investor that had 100 shares of Astellas Pharma stock prior to the split would have 125 shares after the split.

What is Astellas Pharma's stock symbol?

Astellas Pharma trades on the OTCMKTS under the ticker symbol "ALPMY."

How do I buy shares of Astellas Pharma?

Shares of ALPMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Astellas Pharma's stock price today?

One share of ALPMY stock can currently be purchased for approximately $14.96.

How much money does Astellas Pharma make?

Astellas Pharma (OTCMKTS:ALPMY) has a market capitalization of $27.46 billion and generates $11.55 billion in revenue each year. The company earns $1.10 billion in net income (profit) each year or $0.55 on an earnings per share basis.

How many employees does Astellas Pharma have?

Astellas Pharma employs 15,455 workers across the globe.

Does Astellas Pharma have any subsidiaries?

The following companies are subsidiares of Astellas Pharma: Agensys, Astellas B.V, Astellas Farma Brasil Importaçáo e Distribuiçáo de Medicamentos Ltda., Astellas Farma Colombia SAS, Astellas Farma Limitada, Astellas Green Supply Inc., Astellas Innovation Management LLC, Astellas Institute for Regenerative Medicine, Astellas Ireland Co. Limited, Astellas Pharma, Astellas Pharma A.G., Astellas Pharma A/S, Astellas Pharma Australia Pty Ltd., Astellas Pharma B.V., Astellas Pharma Canada Inc., Astellas Pharma China Inc., Astellas Pharma Co. Limited, Astellas Pharma DMCC, Astellas Pharma Europe B.V., Astellas Pharma Europe Ltd., Astellas Pharma Ges.m.b.H, Astellas Pharma Global Development Inc., Astellas Pharma GmbH, Astellas Pharma Hong Kong Co. Ltd., Astellas Pharma India Private Limited, Astellas Pharma Kft., Astellas Pharma Korea Inc., Astellas Pharma Ltd., Astellas Pharma Malaysia Sdn. Bhd., Astellas Pharma Philippines Inc., Astellas Pharma S.A., Astellas Pharma S.A.S, Astellas Pharma S.p.A., Astellas Pharma Singapore Pte. Ltd., Astellas Pharma Sp.zo.o., Astellas Pharma Taiwan Inc., Astellas Pharma Tech Co. Ltd., Astellas Pharma US Inc., Astellas Pharma d.o.o., Astellas Pharma ilaç Ticaret ve Sanayi A.Ş., Astellas Pharma s.r.o, Astellas Pharmaceuticals AEBE, Astellas Research Institute of America LLC, Astellas US Holding Inc., Astellas US LLC, Astellas US Technologies Inc., Astellas Venture Management LLC, Audentes Therapeutics, Ganymed Pharmaceuticals, Iota Biosciences, JSC Astellas Pharma, Mitobridge, Nanna Therapeutics, OSI Pharmaceuticals, Ocata Therapeutics, Ogeda, P.T. Astellas Pharma Indonesia, Potenza Therapeutics, Quethera, The Representative Office of Astellas Pharma Singapore Pte. Ltd. in Vietnam, Universal Cells Inc., and Xyphos.
Read More

When was Astellas Pharma founded?

Astellas Pharma was founded in 1923.

How can I contact Astellas Pharma?

Astellas Pharma's mailing address is 2-5-1 Nihonbashi-Honcho Chuo-Ku, Tokyo M0, 103-8411. The official website for Astellas Pharma is www.astellas.com. The company can be reached via phone at (133) 244-3000.

This page (OTCMKTS:ALPMY) was last updated on 8/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.